Previous 10 | Next 10 |
Revenue of $3,652 million GAAP Net Income of $289 million, Adjusted EBITDA of $851 million GAAP Diluted Earnings per Share of $1.53, Adjusted Diluted Earnings per Share of $2.45 R&D Solutions quarterly bookings of $2.6 billion, representing book-to-bill ratio of 1.28x ...
2023-04-26 12:13:10 ET IQVIA ( NYSE: IQV ) is scheduled to announce Q1 earnings results on Thursday, April 27th, before market open. The consensus EPS Estimate is $2.41 (-2.4% Y/Y) and the consensus Revenue Estimate is $3.61B (+1.1% Y/Y). Over the last 2 years, IQV h...
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Gr...
2023-04-12 17:19:34 ET Summary Dealreporter article says that multiple PE firms are bidding for the company and even named advisors the company has hired. Private equity math works given relatively low current leverage and high cash generation. Even though the stock is decentl...
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings releas...
2023-03-29 04:02:00 ET Summary DEI is sometimes viewed as a 'softer' policy topic that doesn’t factor into investor outcomes. We think that’s a mistake. One of the most compelling reasons for implementing DEI initiatives is from a cost-management perspective. Reg...
2023-03-17 11:01:39 ET Truist has initiated IQVIA Holdings ( NYSE: IQV ) with a buy rating saying that the company is set to further benefit from its "differentiated" contract research organization ("CRO") segment. The firm has a $265 price target (~35% upside based on Thu...
In 2022, there was a decline of 1% in non-COVID trial activity compared to 2021, but using 2019 as the pre-pandemic baseline, there was an increase of 8% in trial activity in 2012. Clinical development productivity rebounded dramatically in 2022 with a 27% increase, reversing a 10-year do...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET. A live audio webcast of the pres...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 10:00:13 ET Jailendra Singh from Truist Financial issued a price target of $300.00 for IQV on 2024-07-23 09:26:00. The adjusted price target was set to $300.00. At the time of the announcement, IQV was trading at $240.265. The overall price target consensus is...
2024-07-23 10:00:11 ET Elizabeth Anderson from Evercore ISI issued a price target of $270.00 for IQV on 2024-07-23 08:59:00. The adjusted price target was set to $270.00. At the time of the announcement, IQV was trading at $239.5. The overall price target consensus is at...
2024-07-23 07:00:06 ET Luke Sergott from Barclays issued a price target of $275.00 for IQV on 2024-07-23 05:25:00. The adjusted price target was set to $275.00. At the time of the announcement, IQV was trading at $245.23. The overall price target consensus is at $273.93 ...